Weiguo Su

CEO & CSO at Chi-Med

Dr. Su has been an Executive Director of the Company since 2017. He is also a member of the Technical Committee of the Company. He was a member of the Nomination Committee of the Company from April 2019 to December 2020. He has been the Executive Vice President and Chief Scientific Officer of the Company since 2012. Dr. Su has headed all drug discovery and research since he joined the Company, including master-minding the Company’s scientific strategy, being a key leader of the Oncology/Immunology operations, and being responsible for the discovery of each and every small molecule drug candidate in the Company’s product pipeline. Prior to joining the Company in 2005, Dr. Su spent 15 years with the U.S. Research and Development Department of Pfizer, Inc. with his last position as director of the Medicinal Chemistry Department.

In March 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drugs R&D Leaders in China.

Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai. He completed a Ph.D. and Post-doctoral Fellowship in Chemistry at Harvard University under the guidance of Nobel Laureate Professor E. J. Corey.

Timeline

  • CEO & CSO

    Current role

View in org chart